Japan Pharmas Seek Advantages In High Hay Fever Season
This article was originally published in PharmAsia News
Japanese drug makers seek to expand their lines of hay fever drugs to take advantage of a heavy season for the ailment by offering year-round offshoots. Some firms are emphasizing protection against house dust and pollen from a Japanese cypress while others seek to make over-the-counter versions of prescription drugs. The pollen count in Japan this spring is projected to be as much as 200 percent higher than last year in parts of the country. (Click here for more - a subscription may be required
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.